SG Americas Securities
INBX icon

SG Americas Securities’s Inhibrx INBX Stock Holding History

SG Americas Securities’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,088
Closed -$1.27M – 3458
2025
Q4 		$1.27M Buy
+16,088
New +$1.1M ﹤0.01% 1813

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SG Americas Securities's INBX Position: Q1 2026 in Review

SG Americas Securities sold out of Inhibrx (INBX) in Q1 2026, closing a stake of 16,088 shares — an estimated $1.27M sold.

SG Americas Securities first reported a position in INBX in Q4 2025 and held it in 1 quarter. The position peaked at $1.27M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • SG Americas Securities reported no remaining Inhibrx position as of Q1 2026 after selling out during the quarter.
  • SG Americas Securities sold 16,088 Inhibrx shares in Q1 2026, an estimated $1.27M.
  • SG Americas Securities first reported a position in Inhibrx in Q4 2025 and held it in 1 quarter.
  • SG Americas Securities's Inhibrx position peaked at $1.27M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.